Basic Information
| LncRNA/CircRNA Name | MALAT1 |
| Synonyms | MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853 |
| Region | GRCh38_11:65497688-65506516 |
| Ensemble | ENSG00000251562 |
| Refseq | NR_002819 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | multiple myeloma |
| ICD-0-3 | C42.1 |
| Methods | in vitro knockdown, RIP etc. |
| Sample | cell lines (MM.1S, H929, RPMI8226, HEK293T), MM tissue |
| Expression Pattern | up-regulated |
| Function Description | Overexpression of MALAT1 has been demonstrated to related to poor prognosis of multiple myeloma (MM) patients. MALAT1 plays important roles in MM DNA repair and cell death. We found bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) and MM express elevated MALAT1 and involve in alternative non-homozygous end joining (A-NHEJ) pathway by binding to PARP1 and LIG3, two key components of the A-NHEJ protein complex. Degradation of the MALAT1 RNA by RNase H using antisense gapmer DNA oligos in MM cells stimulated poly-ADP-ribosylation of nuclear proteins, defected the DNA repair pathway, and further provoked apoptotic pathways. Anti-MALAT1 therapy combined with PARP1 inhibitor or proteasome inhibitor in MM cells showed a synergistic effect in vitro. |
| Pubmed ID | 29632340 |
| Year | 2018 |
| Title | Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. |
External Links
| Links for MALAT1 | GenBank HGNC NONCODE |
| Links for multiple myeloma | OMIM COSMIC |